The treatment and management of neuroleptic-resistant schizophrenic patients, who comprise 5 to 25 percent of all patients with that diagnosis, are major problems for psychiatry. In addition, another large group of schizophrenic patients, perhaps 5 to 20 percent, are intolerant of therapeutic dosages of neuroleptic drugs because of extrapyramidal symptoms, including akathisia, parkinsonism, and tardive dyskinesia. Because about 60 percent of neurolepticresistant schizophrenic patients respond to clozapine and a large percentage of neuroleptic-intolerant patients are able to tolerate clozapine, it should be considered the treatment of choice for such patients until other therapies are proven to be superior. A trial of clozapine alone should usually be continued for up to 6 months before it is terminated or supplemental agents are tried. Plasma levels of clozapine may be useful to guide dosage. The major side effects of clozapine are granulocytopenia or agranulocytosis (l%-2%) and a dose-related increase in the incidence of generalized seizures. Psychosodal treatments such as education of the patient and the family about the nature of the illness, rehabilitation programs, social skills training, and assistance in housing are generally needed to obtain optimal benefit from clozapine, as with other somatic therapies. If clozapine is unavailable, unacceptable, or not tolerated, a variety of approaches may be employed to supplement typical antipsychotic drugs for patients who do not respond adequately to these agents alone. These include lithium; electroconvulsive therapy; carbamazepine or valproic acid; benzodiazepines; antidepressant drugs; reserpine; L-dopa and amphetamine; opioid drugs; calcium channel blockers; and miscellaneous other pharmacologic approaches. The evidence for the efficacy of these ancillary somatic therapies in treatmentresistant patients is relatively weak. Polypharmacy should be tried only for discrete periods and with clear goals. If these are not achieved, supplemental medications should be discontinued. Psychosurgery is not a recommended alternative at this time.
amine; opioid drugs; calcium channel blockers; and miscellaneous other pharmacologic approaches. The evidence for the efficacy of these ancillary somatic therapies in treatmentresistant patients is relatively weak. Polypharmacy should be tried only for discrete periods and with clear goals. If these are not achieved, supplemental medications should be discontinued. Psychosurgery is not a recommended alternative at this time.
The main treatment for schizophrenia unquestionably, remains the multiple classes of antipsychotic drugs, including the phenothiazines, butyrophenones, indolones (e.g., molindone), thioxanthenes (e.g., thiothixene), diphenylbutylpiperidines (e.g., pimozide), dibenzoxazepines (e.g., loxapine), and benzamides (e.g., sulpiride; . Accurate figures on the responsiveness of schizophrenic patients to typical antipsychotic drugs are not readily available. This is, in part, due to lack of studies that focus on the outcome of schizophrenia in all relevant dimensions, not only psychopathology. The collaborative study carried out by the National Institute of Mental Health in schizophrenic patients with an acute exacerbation, which emphasized symptomatic response, indicated that 3 percent worsened, 5 percent showed no change, 22 percent were minimally improved, and 69 percent were much improved (Cole et al. 1964 (Cole et al. , 1966 . However, this study used diagnostic criteria that do not reflect current standards and, moreover.
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represents the result of short-term hospital treatment. A recent review suggests a consensus that 5 to 25 percent of schizophrenic patients may be considered unresponsive to antipsychotic drug therapy to a clinically significant extent (Brenner et al. 1990 ). This estimate is based mainly on effects on symptomatology, especially positive symptoms such as delusions and hallucinations. However, there are, in addition to positive and negative symptoms, at least three other important outcome measures in schizophrenia: social function, employment, and rehospitalization (Strauss and Carpenter 1972) . These four outcome measures are independent of each other to a greater extent than is generally appreciated (Strauss and Carpenter 1972) . There are no studies that demonstrate the outcome of neuroleptic treatment in schizophrenia using all these criteria.
It has been suggested that the goal of treatment in schizophrenia should be to restore function to the premorbid level, which may be within the normal range, for the four measures cited above ). There are, of course, many schizophrenic patients who had impaired premorbid function with regard to social function and age-appropriate school or work achievement before the first overt psychotic period. These are usually the insidious-onset schizophrenic patients who frequently manifest some stigmata of schizophrenia from a very early age. Restoring these patients to their premorbid level is not a totally satisfactory goal of treatment but is, in general, the most ambitious and achievable aim with the current group of treatments. Based on these admittedly ambitious and multifaceted criteria ), many more than 5 to 25 percent of schizophrenic patients are treatment resistant. For some issues of public policy, for example, social security disability and eligibility for clozapine at public expense, some formal criteria for treatment response or resistance are needed; Brenner and colleagues (1990) have proposed standards in this area.
Opinions of the patient, family members, and clinicians as to the adequacy of response to drug treatment, in many cases, are personalized and idiosyncratic. It is possible that even patients with mild symptoms will be dissatisfied if they do not achieve desired goals in social function, work, and interpersonal relations. There are no data available to determine how many schizophrenic patients meet the criterion of returning to their best premorbid level of functioning, a somewhat more rigorous criterion than that of Brenner's level I (clinical remission), which stresses positive symptom remission and absence of need for close supervision (Brenner et al. 1990) .
For the purpose of this review, treatment-resistant schizophrenia may be characterized by (1) persistent delusions, hallucinations, or thought disorder; or (2) pervasive negative symptoms such as withdrawal, anhedonia, poverty of thought content, defect in volition, and lack of energy. When at least one of the positive symptoms is present to a marked extent, or several of the negative symptoms are present to at least a moderate extent in combination with slight-tomoderate positive symptoms, there is little dispute that such patients are resistant to treatment and might be candidates for alternative forms of therapy, especially novel drug treatments. When only negative symptoms are present or when positive symptoms are mild, or when there is a partial improvement from a more severely ill state, elements of both treatment responsiveness and resistance are present. Subjective considerations and level of social function will play a major role in determining the desire for modification of the treatment regimen in such cases. In addition to treatment-resistant patients, neuroleptic-intolerant patients usually derive limited benefit from neuroleptic drugs. This is usually due to parkinsonian side effects or moderate-to-severe tardive dyskinesia (TD) or tardive dystonia.
Although pharmacotherapy is the undisputed cornerstone of the treatment of schizophrenia, other somatic therapies such as electroconvulsive therapy (ECT) may be of value in some patients, even those who are treatment resistant (Milstein et al. 1990) . Psychosurgery is rarely used to treat schizophrenia because it is unclear that it is useful (National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research 1977) . A wide range of psychosocial therapies, some of which have been more fully developed recently (Ekdawi 1990; Falloon 1990 )-such as social skills training, cognitive retraining, individual and group therapy, family education, case management, special assistance for housing, and job or school placement-are often of help to patients whose response to neuroleptic drugs is limited (Mosher and Keith 1980; Mosher and Meltzer 1980) . It is beyond the scope of this article to consider these therapies. Brenner and colleagues (1990) have provided a brief list of the psychosocial principles used in the treatment of schizophrenia, emphasizing the importance of targeting specific symptoms with multidisciplinary, multifaceted intervention based on social learning principles, therapeutic community, and educational meth-ods. They emphasize that these treatments may have to be applied for years, and that a patient's tolerance to their sometimes stressful nature must be carefully gauged. However, the expert clinician will judiciously employ these other therapies whenever possible.
The purpose of this review will be to consider the use of somatic therapies, especially clozapine, the first antipsychotic drug demonstrated to be effective in a large number of treatment-resistant schizophrenic patients (Kane et al. 1988a; Meltzer et al. 1989b ) and in neurolepticintolerant schizophrenic patients. Because clozapine's use is restricted by its side-effect profile, the use of other treatments to complement typical neuroleptic drugs will also be considered. Brief consideration of other novel, atypical antipsychotic drugs and the role of ECT and psychosurgery in treatment-resistant schizophrenia will also be provided.
Adequacy of Clinical Trials With Standard Treatments
The optimal use of typical neuroleptic drugs in schizophrenia has been covered extensively (Hollister 1970 Determination of neuroleptic plasma levels is of little benefit in improving response rate but may help identify noncompliant patients or patients whose plasma levels have been reduced by enzyme inducers such as carbamazepine (Meltzer et al. 1983a; Van Putten et al. 1991) . Determination of plasma prolactin (PRL) levels may be a more convenient way to achieve the same goal (Meltzer et al. 1983a ). There is modest evidence for an optimal range of plasma levels for some antipsychotic drugs, for example, haloperidol (2-12 ng/ml), fluphenazine (0.2-2.0 ng/ml), perphenazine (0.8-2.4 ng/ml), and chlorpromazine (30-100 ng/ml). Van Putten and colleagues (1991) There is evidence that its severity may not be progressive (Gardos et al. 1983; Kane et al. 1984) . In such cases, the presence of TD does not necessarily mean that neuroleptic treatment should be discontinued, but only that dosage should be lowered to the least amount needed to achieve remission of psychotic symptoms. It is conceivable, however, that less than optimal relief of psychosis results from such a strategy. In a small group of patients, TD may be severe, progress rapidly, or be intolerable whatever its extent. For them, a clozapine trial may be indicated provided the risk/benefit is duly considered with the patient or guardian. The use of clozapine in patients with established TD will be discussed subsequently.
Clozapine
The Wander Laboratories synthesized clozapine in 1959 in the search for an antipsychotic drug that produced fewer EPS (Schmutz and Eichenberger 1982) . Although loxapine and amoxapine are also dibenzodiazepines, both have typical neuroleptic properties, that is, they cause significant EPS and large increases in plasma PRL levels in man (Robertson et al. 1982) . Although clozapine was found not to produce catalepsy in rats, it had the profile of an antipsychotic compound in preclinical models; for example, it blocked the conditioned avoidance response (Stille et al. 1976) . After clinical testing confirmed its effectiveness as an antipsychotic with few or no EPS (Hippius 1980), clozapine was introduced in the early 1960s in a number of Western European countries. However, in 1975 eight patients in Finland who were receiving clozapine (plus other drugs) died from infectious diseases after developing agranulocytosis (Amsler et al. 1977) .
These deaths led to the withdrawal of clozapine from unrestricted use in Europe. However, some patients who had responded well to clozapine not only relapsed following its withdrawal, but did so poorly after reinstitution of typical neuroleptic drug treatment that the use of clozapine on a limited basis was permitted in treatment-resistant schizophrenic patients in several European countries. Results of this treatment with clozapine were generally favorable and included effective control of psychotic symptoms, ability of some treatment-resistant patients to be discharged from hospital, and better work function (Povlsen et al. 1985; . Clozapine was also found to be associated with a remarkably low rate of TD (see Casey 1989 for a review) and was shown not to increase plasma PRL levels in man ).
In the United States clozapine was withdrawn from phase II clinical trials because of the Finnish deaths, but a few investigators were permitted to use it on a compassionate-use basis in treatment-resistant cases with or without TD. Remarkable improvement in TD and psychotic symptomatology was observed in some patients (Meltzer and Luchins 1984) . There were also at least 11 studies worldwide in which the efficacy of clozapine was compared with standard neuroleptic drugs in patients with schizophrenia or other psychoses, some of whom were treatment resistant. These studies generally used lower doses of clozapine (^ 300 mg/day). In six studies, clozapine appeared to have an advantage over typical neuroleptic drugs with regard to global psychopathology or specific positive symptoms (Ekblom and Haggstrom 1974; Fischer-Cornelssen et al. 1974; Gerlach et al. 1974; Vencovsky et al. 1975; Gelenberg and Doller 1979; Shopsin et al. 1979) . In five studies, clozapine appeared to be equal to typical antipsychotic drugs (Angst et al. 1971; Singer and Law 1974; Chiu et al. 1976; Fischer-Cornelssen et al. 1976; Guirguis et al. 1977) .
Because of the evidence that clozapine might have superior antipsychotic efficacy with few or no EPS compared to typical neuroleptic drugs and be less likely to produce TD, a controlled trial was initiated in the United States. Its goal was to determine whether clozapine was sufficiently more effective than standard neuroleptics in treatment-resistant schizophrenic patients to warrant the significantly higher risk of agranulocytosis (l%-2% based on European experience compared to an incidence of 0.05%-0.1% with typical neuroleptic drugs; Claas 1989). Because of the risk of agranulocytosis, the trial included only schizophrenic patients who had failed to respond to all other available therapies. A total of 318 severely ill, chronic schizophrenic patients who had failed to respond to three or more neuroleptic drugs from at least two different chemical classes were selected for an 18-hospital multicenter trial (Kane et al. 1988a ). In the initial open phase, 81.3 percent of the patients did not respond to a 6-week trial of haloperidol, and only 2 percent were classified as responders by criteria that included a 20 percent decrease in the total Brief Psychiatric Rating Scale (BPRS; Overall and Gorham 1962) score. Following this, the 248 nonresponders and 22 patients who could not tolerate haloperidol because of EPS (despite use of benzotropine) were randomly assigned to clozapine alone or chlorpromazine plus benztropine for a 6-week trial. Response was defined as a This pivotal study led to approval of clozapine for use in the United States in treatment-resistant schizophrenic patients and patients who cannot tolerate neuroleptic drugs because of EPS or severe TD. However, clozapine was not approved for use in schizophrenic patients who have an adequate response to typical antipsychotic drugs, although no formal attempt was made to specify the criteria of an adequate response.
Clinical Pharmacology. Following oral administration, clozapine is absorbed in the small intestine (absorption half-life = 40 min). Oral bioavailability varies from 90 to 95 percent (Choc et al. 1987; Cheng et al. 1988) . Peak plasma levels are achieved in 1 to 4 hours. Ninety-five percent of the clozapine in plasma is protein bound. Clozapine is almost completely metabolized in the liver through demethylation and oxidation (Bailey et al 1990) ; both metabolites are inactive (Schmutz and Eichenberger 1982) . The half-life after twice-aday dosing at the steady state is about 14 hours (range = 6-33) (Bailey et al. 1990 ). Thus, steadystate levels should be achieved after 1 week of constant twice-daily dosings. Mean plasma levels of clozapine average 200 to 400 ng/ml (range = 60-1000) (Choc et al. 1987; Cheng et al. 1988; Ackenheil 1989; Haring et al. 1989 ).
Administration. Clozapine treatment should be initiated with patients in a drug-free condition if possible, both for safety reasons and in order to determine if the patient responds to clozapine alone. In particular, initiation of clozapine treatment in patients receiving a combination of one or more neuroleptics, together with carbamazepine, lithium, benzodiazepines, or antidepressants should be avoided. It is quite possible that this is not only an unsafe practice, but that it also might diminish the effectiveness of clozapine rather than achieve an additive effect. Clozapine's mechanism of action is not fully understood. It clearly is not due to simple dopamine (DA) D 2 receptor blockade and resultant changes in dopaminergic activity as has been suggested for the typical neuroleptic drugs. Rather, it may well be due to weak D 2 receptor blockade in relation to potent serotonin (5HT 2 ), D 2 , or D 4 receptor blockade (see Meltzer 1991 for review) . If this is the case, potent D 2 receptor blockade with concomitant neuroleptic therapy, even at low doses, may diminish the benefits from clozapine. Controlled trials of combined neuroleptic plus clozapine therapy at the outset of treatment with clozapine are needed. In the absence of such data, clozapine alone is the preferred treatment approach in the author's opinion.
If patients have been receiving a multiple psychotropic drug regimen, they should first be switched to a single high-potency neuroleptic such as fluphenazine or haloperidol at as low a dose as possible consistent with safety, comfort, and compliance, even if this leads to an exacerbation of psychotic symptoms. Withdrawal from the single neuroleptic should then precede initiation of clozapine treatment whenever possible. If that is not possible, clozapine should be added to the high-potency neuroleptic. As the dose of clozapine is increased to 200 to 300 mg/day over a 2-week period, the neuroleptic dose should be decreased and eventually eliminated, usually within another 2 weeks.
Clozapine is available in 25 mg and 100 mg tablets in the United States. The usual starting dose is 25 mg once or twice a day. In some European countries, a parenteral preparation for intramuscular use is available; however, it is known to cause local pain at the site of injection.
It is possible to start clozapine on outpatients with close monitoring of blood pressure, pulse, and sedation to determine when the dose can be raised, but this requires good cooperation from patients and their families or caregivers. Many clinicians will find it safest and most convenient to begin clozapine treatment on an inpatient basis. The dose of clozapine is gradually increased by 25 mg every other day until it reaches 100 mg. It can then be increased by 50 mg every other day until a dose of 300 to 450 mg/day is reached, usually by the end of 2 weeks. The dose usually should not exceed 450 to 600 mg/day because the risk of seizures is dose related (see below). If response at 600 mg/day is unsatisfactory, dosage can be further increased up to a maximum of 900 mg/day. There are no fixed-dose studies to determine optimal dosage. In Europe, clinical practice has been to use doses of 200 to 300 mg/day (Naber et al. 1989) or lower, whereas in the United States, doses of 400 to 600 mg/day are most common (Kane et al. 1988a; Meltzer et al. 1989o, 1989b . The mean dosage in 145 patients at University Hospitals of Cleveland was 522 ± 208 mg/day (range = 25-900 mg); 68 (45.9%) were given 600 to 900 mg/day. A total of 13 (9.0%) patients received 900 mg/day. It may be possible to lower the dosage during the maintenance phase. The dosage of ciozapine required in the elderly is less than that in younger patients. In four patients ages 60 to 68 whom we have treated, the mean dose was 275 ± 96 mg/day (range = 200-400 mg), significantly lower than the dosage given to younger patients.
Outcome. Of 192 patients begun on ciozapine (including 47 at the Cleveland Veterans Administration Medical Center), 122 (63.5%) have continued treatment for 3 months to 5V4 years (median = 31 months). The time course of dropouts and the reasons for discontinuing ciozapine are given in tables 1 and 2. The majority of subjects who dropped out (42 of 70, 60%) did so after 3 months. The major reason for discontinuation was noncompliance (45.7%) followed by adverse events other than hematologic (21.4%) and lack of efficacy (11.4%).
Of the total sample, 3 of 192 (1.56%) developed agranulocytosis while 8 of 192 (4.2%) did not respond well enough to continue on clinical grounds alone. Agranulocytosis occurred between 3 and 12 months. The noncompliant patients were individuals who may have been responding well but who declined to continue taking ciozapine. Noncompliance was a reason for dropping out throughout the period under study. Although data about the noncompliance rate for atypical antipsychotic drugs in this population are not available, my clinical experience is that it is much higher than the incidence with ciozapine (32 of 192, 16.7%).
About 30 percent of hospitalized treatment-resistant schizophrenic patients respond to ciozapine in the first 6 weeks of treatment with a re- duction of symptoms and improvement in ward behavior (Kane et al. 1988a ). Meltzer and colleagues (1990) reported a similar percentage of response in treatment-resistant cases. Another 20 percent of treatmentresistant patients may respond between 6 weeks and 3 months of treatment and another 10 to 20 percent by the end of 6 months . Anecdotal reports of patients who show their first improvement between 6 and 15 months have been reported to the author (personal communication, 1991) . We examined the time of response to ciozapine in 43 treatmentresistant schizophrenic patients who completed a 6-month trial of ciozapine, had an admission total BPRS score ^ 45, and for whom BPRS scores were available at 6 weeks, 3 months, and 6 months. Any subject with lower BPRS scores at baseline, with missing data, or who had failed to continue on ciozapine for any reason (e.g., side effects, noncompliance, failure to respond) was not included in this analysis. Of the 43 patients, 25 (58.1%) first had a decrease in BPRS total score of ^ 20% by 6 weeks. Another 10 patients (23.3%) first had a decrease of this amount at 3 months, and two (4.6%) first had a decrease at 6 months. Six patients (14%) never improved by these criteria. Fifteen of the 25 patients (60%) who first improved at 6 weeks remained responders at all subsequent periods. Ten (40%) did not meet these criteria at 3 or 6 months, or both. These data illustrate that some patients have a delayed response to ciozapine. It should be noted that this response rate is high because it does not consider any of the dropouts. Overall, we still find that about 60 percent of treatment-resistant patients begun on ciozapine will remain on it at 6 months (Meltzer 1992) . Improvement occurs in both positive and negative symptoms (Kane et al. 1988a; Meltzer et al. 1989b Meltzer et al. , 1990 ), which may be independent of each other and should be evaluated separately as measures of good outcome. The change in BPRS total, positive, and negative scores in the 43 patients previously discussed is given in figure 1. Repeated measures analysis of variance (ANOVA) showed significant time effects for total BPRS scores (F = 31.2; df = 3,40; p = 0.0001), BPRS positive symptoms (F = 28.4; df = 3,40; p = 0.0001), and BPRS negative symptoms (F = 3.21; df = 3,40; p = 0.03). Post-hoc tests (least significant difference) showed that the 6-week and 3-and 6-month time points were all different from baseline with the exception of the negative symptom ratings at 6 months and baseline. It is clear from these data that improvement, at least in terms of total BPRS scores, levels off over time. However, mean BPRS scores in large groups of subjects obscure the marked and usually steady improvement in significant numbers of subjects. Twenty of 55 (36.4%) patients treated with clozapine for 12 months in our program had marked (^40%) decreases in BPRS total 
TIME (MONTHS)
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Response to Clozapine as a Function of Age. The effect of age on response to clozapine was examined by multiple regression in a group of 90 patients who remained on clozapine for at least 6 months. The age of the patients was 34.5 ± 10.3 years (range = 16-68). Specific ratings of psychopathology at 6 months were predicted by age after adjusting for baseline. The F values and p values for these predictors are given in table 3. Older age predicted higher levels of psychopathology and lower Global Assessment Scale (GAS; Endicott et al. 1976 ) scores (poorer outcome) at 6 months. Improvement in paranoid/depression and quality of life was independent of age. Improvement at 6 weeks was not usually related to age. These results suggest younger patients respond better to clozapine.
Augmentation. Clozapine may be ineffective despite a trial of adequate dose (up to 900 mg/day) or duration (up to 6 months) in up to 40 percent of treatment-resistant patients. Finally, there may be cases with a partial response to clozapine, but the extent of improvement in positive or negative symptoms, social function, or quality of life is less than is desired by the patient, the family, or the clinician. Addition of a high-potency neuroleptic drug such as haloperidol in clozapine nonresponders has been used in such cases (Povlsen et al. 1985) . However, there have been no controlled trials demonstrating the usefulness of combined treatment with typical neuroleptics (Meltzer et al. 1989c (Meltzer et al. , 1989d . There are as yet no studies to indicate what other strategies might be helpful to supplement clozapine. It is likely that clinicians will choose treatments based on symptomatic criteria, for example, antidepressants or anxiolytics for patients whose unrelieved symptomatology is of either type. We have found fluoxetine or buspirone useful in a small number of such patients (Meltzer and Bastani, unpublished observation) . Improvement in social functioning during clozapine treatment has been reported ). Meltzer and colleagues (1990) reported that mean Quality of Life Scale (Heinrichs et al. 1984) scores improved by 59.9 percent over a 6-month period in 38 clozapinetreated patients. All aspects of social function rated by this scale were found to improve. Even some previously regressed patients with marked defect symptoms have been able to work after clozapine Meltzer et al. 1990 ). The marked reduction in rehospitalization following clozapine contributes to improvement in social function. This process can be facilitated by psychosocial treatments, such as education about schizophrenia, social skills training, housing support, and group therapy. Working with families to minimize unrealistic expectations or criticism and interference with autonomy and to maximize constructive support and reinforcement of renewed social behaviors is particularly important ).
Plasma Levels. There is some evidence that determination of plasma levels of clozapine may be clinically useful. Although three early studies have reported a positive relationship between plasma levels of clozapine and clinical response (Akenheil et al. 1977; Thorup and Fog 1977; Brau et al 1978) , a positive relationship was found by Perry and colleagues (1991) and we have obtained similar data (Hasagawa et al., submitted for publication) .
In 23 patients who had a decrease in BPRS total score of <, 20 percent by 6 months, we found clozapine levels of 429.5 ± 248.8 ng/ml compared to 288.8 ± 188.7 ng/ml in 17 patients with a less than 20 percent response (Hasagawa et al., submitted for publication). The dose of clozapine at the time the blood was drawn in the good responders was not significantly higher than in the other group (481.8 ± 223.8 mg/day vs. 395.3 ± 189.3 mg/day, p = 0.10). There was a trend for dose and plasma clozapine levels to be correlated (rho = 0.29, p = 0.07). Plasma clozapine concentration and weight were correlated (rho = 0.35, p = 0.03). We observed a strong effect of smoking on clozapine levels. For smokers (n = 30), plasma clozapine levels were 460.8 ± 291.2 ng/ml (p = 0.03). There was no significant difference in dosage between smokers and nonsmokers (464.2 ± 244.0 vs. 415.0 ± 185.1 ng/ml). These results suggest that smoking should be discouraged in patients on clozapine; if it cannot be reduced or eliminated, higher doses may be needed.
It seems likely that measurement of plasma levels of clozapine will be clinically useful. Dosage may be guided by plasma levels as well as side effects and clinical response. Patients with poor response should definitely be checked for adequate plasma levels. It may be prudent in very carefully selected cases to exceed the recommended limit of 900 mg/day if plasma levels are less than 450 ng/ml, and there are no major cardiovascular or other side effects.
Drug Interactions. The following drugs may interact adversely with clozapine and should be avoided or their use closely monitored: alcohol, central nervous system (CNS) depressants, anticholinergic drugs (except to treat hypersalivation), and drugs that may suppress bone marrow function, especially carbamazepine.
There has been considerable concern about the combination of clozapine and benzodiazepines because of reports of respiratory arrest. The evidence relating some of these events to benzodiazepine usage is not strong. Sudden death in schizophrenic patients has been reported frequently in the neuroleptic era. Whether benzodiazepines increase the frequency of respiratory arrest or sudden death due to other causes in clozapine-treated patients and whether the risk with clozapine is greater than that with other drugs are unclear. Benzodiazepines are sometimes needed in managing schizophrenic patients when initiating clozapine treatment in neurolepticfree patients. Clinicians need to consider the risk-benefit of combining benzodiazepines and clozapine versus the disadvantages of continued use of typical neuroleptic drugs. When the combination is first given, it may be desirable to have the patient hospitalized or remain in the outpatient setting for 2 to 4 hours.
Clozapine in combination with lithium has been implicated in several cases of neuroleptic malignant syndrome (NMS) (Pope et al. 1986 ). The incidence seems suspiciously high because of the small number of patients treated with the combination. Lithium should be used only if hypomanic symptoms are not adequately controlled with clozapine.
Drugs that are hepatic drug metabolizing enzyme inducers may be expected to lower clozapine levels. This may occur with anticonvulsant drugs such as phenytoin or valproate or antidepressants . If combination therapy is given, it may be useful to measure plasma levels or at least be alert to the possible need to increase the dose of clozapine.
One case of possible influence of trifluoperazine in causing an end to the normalization of white blood cell (WBC) count following discontinuation of clozapine due to agranulocytosis has been reported (Adams et al. 1990 ). However, it is not clear that trifluoperazine was at fault in this case.
The possibility that psychotropic drugs affect the monoaminergic systems that clozapine acts upon needs to be considered. The biological basis for this has been discussed previously. Addition of typical neuroleptic drugs, even in small amounts, to clozapine may cause increased EPS and possibly diminish its efficacy in treatment-resistant patients.
Contraindications. Clozapine should not be used in patients with a history of blood dyscrasias or bone marrow suppression, including previous agranulocytosis due to clozapine. It probably could be used in the early stages of the acquired immunodeficiency syndrome (AIDS)-related complex but should be avoided after significant impairment of the immune system has developed. Clozapine should be used very cautiously in the presence of cardiovascular disorders, glaucoma, impaired hepatic or renal function, and prostatic hypertrophy. Clozapine may be used in patients who abuse alcohol or cocaine occasionally but should be avoided in outpatients who are active, heavy substance abusers because of the possibility of toxic interactions between clozapine and these agents.
Indications. Clozapine is indicated mainly for treatment-resistant and neuroleptic-intolerant schizophrenia. Treatment-resistant patients are those who have at least moderate positive or negative symptoms, or both, and impaired social function despite mul-
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tiple trials with typical antipsychotic drugs for adequate durations. Neuroleptic-intolerant patients include those whose TD remains at least moderately severe despite optimal adjustment of neuroleptic dosage.
Although clozapine has no known teratogenic effects, it should be used cautiously in pregnant women. Clozapine-treated women should not nurse their children.
Side Effects
Granulocytopenia and agranulocytosis. The major concern about the use of clozapine is the significant risk of agranulocytosis (Krupp and Barnes 1989) . Before this side effect was identified, many fatalities occurred (Amsler et al. 1977) . The overall incidence of this potentially life-threatening adverse event is now known to be 1 to 2 percent which is 10 to 20 times greater than that of typical neuroleptics. Because of the risk of neutropenia or agranulocytosis, total WBC or neutrophil count must be monitored closely. Sandoz Pharmaceuticals, the manufacturer of clozapine, mentions in the "Basic Text" of the product that the minimum frequency of WBC monitoring should be once a week for the first 18 weeks and at least monthly thereafter. At the current time, such monitoring must continue indefinitely in the United States (Bastani et al. 1989 ). In the United Kingdom, it is done weekly for 18 to 26 weeks and then biweekly. In other countries, it is done weekly until 18 weeks and monthly thereafter. Finland, because of the possible greater vulnerability of its population, uses twice weekly monitoring for the first 18 weeks.
Approximately 80 percent of cases of neutropenia or agranulocytosis occur within the first 18 weeks of treatment. After this time, the continuing risk of either event probably still exceeds that of typical neuroleptic drugs, but to a much smaller extent. In fact, the risk from clozapine after 18 weeks appears not to differ significantly from that due to carbamazepine, which is not routinely monitored. There are as yet no firm data to evaluate the risk/benefit ratio of these various monitoring schemes. For this reason, national data bases on the incidence of agranulocytosis in various ethnic groups should be collected as clozapine usage increases. Until objective data are available, clinicians must follow the direction of local regulatory authorities about the frequency of monitoring. It is possible that in the future the manufacturer of clozapine may recommend less frequent monitoring after the first 6, 12, or 18 months of clozapine treatment.
The fall in WBC count due to clozapine may be abrupt or gradual. Steadily falling WBC counts should increase concern, even if none are below 3000/mm 3 . An abrupt drop of 3000/mm 3 in a single week may also predict agranulocytosis. In such patients, in patients with neutropenia, or in patients with neutrophil counts below 1000/mm 3 , twice weekly WBCs counts with differentials are indicated. When the total WBC count falls below 3000/mm 3 , clozapine must be discontinued and the WBC count with differential followed for 4 weeks.
Management of agranulocytosis should be done in conjunction with a hematologist or an infectious disease specialist. Hospitalization with reverse isolation on a medical unit is indicated. The possibility of death if clozapine is not stopped until after an infection develops may be as high as 50 percent (Krupp and Barnes 1989). Thus, weekly monitoring is strongly indicated. If agranulocytosis develops, prophylactic antibiotic treatment should be considered. Because the duration of agranulocytosis may be longer than for other druginduced blood dyscrasias, neutropenia fever, should it develop, is often a challenging management problem. The bone marrow in patients with clozapine-induced agranulocytosis shows selective loss of granulocyte precursors without indications of aplastic anemia. Upon withdrawal of clozapine, the hematological status usually returns to normal within 2 to 3 weeks. An initial report indicated that human leukocyte antigen (HLA) type may predict the development of agranulocytosis in Ashkenazy Jewish individuals on Long Island, New York (Lieberman et al. 1990 ); however, these results have not been replicated by other investigators, suggesting that the association with HLA typing may be either a regional or an ethnic phenomenon.
It is not clear whether agranulocytosis is due to direct marrow toxicity of clozapine or one of its metabolites, or to the development of antibodies to white cells. Recent studies suggest that a particular clozapine metabolite, desmethylclozapine, may be more toxic to marrow cells, but it remains unclear whether this metabolite is responsible for marrow suppression in patients receiving clozapine (Gerson and Meltzer, in press). Patients who develop agranulocytosis on clozapine once will experience it again within 1 to 4 weeks after being rechallenged. A rechallenge with clozapine should not be tried. Patients who are withdrawn from clozapine during a neutropenic phase (WBC = 2000-3500/mm 3 ) may be rechallenged if WBC and differential are monitored at least weekly. However, these individuals may be at higher risk of developing agranulocytosis.
Seizures. Clozapine, like other antipsychotic medications, can re-VOL. 18, NO. 3, 1992 525 duce the seizure threshold, sometimes resulting in major motor seizures or myoclonus. Patients with epilepsy, a history of seizures of any type, or organic brain disease may be at greater risk. The overall incidence of seizures in patients receiving clozapine is estimated to be 1 to 2 percent at doses below 600 mg/day. Doses larger than 600 mg/day have been reported to be associated with a 6 to 9 percent risk of seizures. Therefore, in patients who do develop seizures, reduction of clozapine dosage to perhaps 50 percent of the dose before the seizure and pharmacological management of seizures might be necessary. Valproate or phenytoin may be most useful for seizure control. Electroencephalographic (EEG) studies may reveal incipient seizures. Both valproate and phenytoin may further diminish clozapine plasma levels, requiring an increase in clozapine dose after initiating anticonvulsant treatment and reducing the risk of seizures in this manner.
At University Hospitals, 9 of 148 (6.1%) of clozapine-treated patients have developed generalized seizures. Two of these patients and two others also developed myoclonus, which may be due to the antiserotonergic properties of clozapine (Sajatovic and Meltzer, submitted for publication).
Cardiovascular effects. The main cardiovascular effects of clozapine are orthostatic hypotension and tachycardia. The ability of clozapine to antagonize alpha adrenergic receptors is responsible for the orthostatic hypotension. The risk of syncope can be significantly reduced by a conservative titration procedure. In most cases, even in the presence of significant initial orthostasis, full therapeutic doses can be achieved. Hypotension was recorded in 20 percent of the patients treated at University Hospitals. This was almost always present after the first few doses of clozapine. Orthostasis was present in 26 percent of the patients at University Hospitals (Meltzer, unpublished observations) . This side effect is most common during the first 5 weeks of treatment, after which adaptation usually occurs. Hypertension may also be observed, most frequently in the first 2 weeks of treatment. Eight percent of the patients treated with clozapine at University Hospitals had elevations of diastolic blood pressure (Meltzer, unpublished observations) .
Tachycardia in patients receiving clozapine is predominantly the result of the anticholinergic effects of clozapine. Mean heart rate can increase 20 to 25 beats per minute and can persist for over 1 year in some patients. As with orthostatic hypotension, this effect is dose dependent. Beta adrenergic blockers have been successfully used to decrease heart rate in some normotensive patients with clozapine-induced tachycardia (Meltzer, unpublished results) . Tachycardia was observed in 45 percent of the patients we have treated with clozapine.
Some electrocardiogram (EKG) abnormalities, usually prolongation of the QT interval, are found in nearly 25 percent of the patients treated with clozapine. Clozapine should be avoided in patients with arrhythmias, including bundle branch block.
Respiratory arrest. Cardiovascular and respiratory dysregulation, sometimes leading to arrest, has been reported following the combination of clozapine and benzodiazepines (Grohmann et al. 1989 ). This dysregulation generally occurs at the onset of treatment with clozapine. In the Grohmann study, it occurred in 4 of 189 patients exposed to the combination-a relative risk of 2.1 percent. This risk may decrease as the duration of the clozapine trial is prolonged. In the absence of further data, this combination should be avoided.
Fever. Benign transient hyperthermia during the first 3 weeks of treatment with clozapine has been reported in 10 to 20 percent of patients. This self-limiting condition may require symptomatic management such as antipyretic medication or temporary withholding of clozapine. In order to diagnose this condition, other causes of fever such as infections secondary to agranulocytosis should be ruled out. Another febrile condition which could be included in the differential diagnosis is NMS. This condition is characterized by hyperpyrexia, muscle rigidity, confusion, and autonomic instability in the presence of laboratory abnormalities such as elevation in white count and creatinine phosphokinase. There are now several cases of NMS in patients receiving clozapine alone (Anderson and Powers 1991; Das Gupta and Young 1991; . NMS has also been reported in patients receiving clozapine in combination with lithium (Pope et al. 1986 ) and with clozapine and carbamazepine (Muller et al. 1988 ). Review of these case reports indicates that in some cases there may be difficulty in distinguishing between NMS and the benign hyperthermia that may accompany initiation of treatment with clozapine.
Extrapyramidal reactions. The absence or very low incidence of EPS is a major clinical advantage associated with clozapine therapy. There have been no reported cases of dystonic reactions in patients receiving clozapine. Further, clozapine was reported to produce an antipsychotic effect without akathisia in a schizo-phrenic patient who experienced severe, disabling akathisia with low-or high-potency conventional neuroleptics ). Cohen and colleagues (1991) recently reported that the prevalence of akathisia in 23 patients treated with clozapine for 1 month or longer (39%) was no different from that in 29 patients receiving standard neuroleptics (45%). Mean scores in both groups were in the mild range. The incidence of moderate or severe akathisia in the clozapine group was 9 percent. The difficulty in distinguishing akathisia and agitation and the absence of a nondrug-treated group make these results difficult to interpret. Akathisia has not been a significant problem in the 150 patients treated with clozapine at University Hospitals (Bastani and Meltzer, unpublished observations). Until recently, there have been no definite reported cases of TD linked to clozapine treatment. Recently, however, Kane and Lieberman (1991) reported three patients who developed the characteristic symptoms of TD after more than 7 years of clozapine usage. These patients had received typical neuroleptic drugs before clozapine. Whether this contributed to the ultimate development of TD is not known. Further study is needed to determine the true incidence of TD with clozapine and whether the development of this side effect is more likely in the elderly and females, as is the case with typical neuroleptic drugs (Kane et al. 1988b) . At the same time, clozapine is sometimes effective in blocking this syndrome (Meltzer and Luchins 1984; . Approximately 30 percent of cases with TD will have a remission and another 10 percent will have a reduction in severity . However, symptoms recur when clozapine is stopped (Small et al. 1987) .
Hypersalivation. During clozapine therapy, almost one-third of the patients complain of hypersalivation. Reduction in the dosage of clozapine or treatment with an anticholinergic medication can alleviate this problem.
Drowsiness and dizziness. Approximately 40 percent of patients on clozapine experience drowsiness and 20 percent experience dizziness. These side effects are most common within the first 2 months of treatment. Although they usually subside as tolerance develops, both can persist. Dizziness is more common in elderly patients. Sedation may limit ability to drive or operate dangerous equipment.
Weight gain. Weight gain may be as troublesome a problem with clozapine as it is with typical neuroleptic drugs. Eleven of 85 (12.9%) patients treated with clozapine showed weight increase of 6 to 20 kg (Povlsen et al. 1985) . In a recent study, clozapineinduced weight gain was noted in 6 of 7 (83.3%) patients ). Nutritional counseling is important to prevent or reverse this side effect when it occurs. On occasion, reduction of the dose is the only effective intervention.
Summary. Treatment-resistant schizophrenic patients should be given a trial of clozapine alone for up to 6 months. Polypharmacy should be avoided, especially the concomitant use of carbamazepine. Clozapine is the only antipsychotic drug that has been found to be more effective than typical neuroleptic drugs in treatment-resistant schizophrenic patients. The effectivness of clozapine will usually manifest as a decrease in positive symptoms, but other outcome dimensions such as negative symptoms, social interaction, work function, rehospitalization, and markedly less EPS may be the major or exclusive measures of its superiority for some patients. It is likely that only a small number of treatment-resistant schizophrenic patients will respond to clozapine with a complete resolution of their illness. Psychiatrists should be alert to clinically significant improvement of a more modest nature. Clozapinetreated patients must be strictly monitored for development of neutropenia or agranulocytosis according to schedules for particular countries.
Other Approaches to Treatment-Resistant Schizophrenia
The majority of other approaches to treatment-resistant schizophrenia discussed here involve supplementation of typical neuroleptic agents by other CNS active agents. These include benzodiazepines; carbamazepine or valproic acid; reserpine; lithium; tricyclic antidepressants; L-dopa and d-amphetamine blockers; opioid drugs; and verapamil. ECT and psychosurgery can also be used. The evidence for the use of these treatments in neuroleptic-refractory schizophrenic patients is discussed here, including a brief discussion of psychosurgery for treatment-resistant schizophrenic patients.
It is beyond the scope of this review to consider atypical antipsychotics that are in early stages of clinical testing (e.g., melperone, amperozide, ICI 204,636, risperidone, sertindole, raclopride, remoxipride, BMY 14802). There is currently little evidence that these agents are effective in treatment-resistant schizophrenic patients, with the possible exception of melperone ). It is, therefore, premature to consider trying these agents in therapy-resistant schizophrenic patients, even on a compassionate need basis. If these agents are approved for use, double-blind trials testing their efficacy in treatment-resistant cases will be necessary before they could be used in such cases. Inclusion of clozapine as well as atypical neuroleptics in such trials would be highly desirable.
Benzodiazepines. Benzodiazepines have been extensively studied as a means of augmenting neuroleptic action in patients with schizophrenia who do not respond to typical antipsychotic drugs (Arana et al. 1986 ). The overall response rate for diazepam (42 of 120, 34%) and a variety of other benzodiazepines (58 of 160, 36.2%) may not be different from placebo (Arana et al. 1986 ). Holden and colleagues (1968) and Ruskin and colleagues (1979) found no effect of addition of chlordiazepoxide or diazepam to neuroleptic-treated, severely ill schizophrenic patients in crossover trials. Although Wolkowitz and colleagues (1988) reported benefits of alprazolam in 5 of 12 schizophrenic patients, these patients were not neuroleptic nonresponders. In another study, chlordiazepoxide (300 mg/day) was found to be effective in diminishing the anxiety, hallucinations, suspiciousness, and unusual thought content BPRS items in three of six schizophrenic patients who had had only minimal response to neuroleptic treatment. Initial anxiety levels were predictive of clinical response (Kellner et al. 1975 ). The addition of diazepam (15 mg/day) to neuroleptics was reported to be superior to placebo in diminishing the BPRS total score as well as the BPRS positive symptom items, suspiciousness and unusual thought content, in a 3-week, placebo-controlled crossover study involving 23 neurolepticresistant patients with schizophrenia or chronic reactive psychoses (Lingjaerde et al. 1979 ). However, Csernansky and colleagues (1988) found no significant effect of the addition of diazepam over placebo in a double-blind study involving 55 neuroleptic-treated schizophrenic outpatients.
The benzodiazepine, estazolam, has been reported to be effective in diminishing positive symptoms and compulsive thoughts in a placebocontrolled double-blind study of 58 neuroleptic-resistant schizophrenic patients (Lingjaerde 1982) . These results were further supported in an open trial of 53 chronic schizophrenics (Astrup and Vatten 1984) .
Csernansky and colleagues (1984) reported alprazolam, a triazolobenzodiazepine, at doses of 5 to 7 mg/day (much higher than the doses used in anxiety disorders), was effective in reducing anxiety and negative symptoms in an open trial in eight schizophrenic patients, seven of whom were receiving neuroleptic drugs. Wolkowitz and colleagues (1986) added alprazolam or placebo to fluphenazine in two treatment-resistant schizophrenic patients. Significant decreases in positive and negative symptoms were noted and there was some suggestion of improvement in anxiety and depression. Both patients relapsed after discontinuing alprazolam. In a subsequent double-blind study in 12 symptomatic, chronic patients treated with fluphenazine, alprazolam slightly decreased ratings of global psychosis thought disorder and paranoia, but not negative symptoms. Symptoms returned after discontinuing alprazolam. Alprazolam appears to be of some benefit in partial responders to standard neuroleptic drugs. However, Csernansky and colleagues (1988) reported that alprazolam was not significantly different from placebo in diminishing negative symptoms in a parallel group study involving 35 treatmentresistant schizophrenic patients. Lorazepam has been reported to be effective in catatonia (McEvoy and Lohr 1984; Greenfeld et al. 1987) .
Although several studies have suggested that patients with higher baseline and anxiety psychosis ratings are more likely to respond to benzodiazepines (Kellner et al. 1975; Kahn et al. 1988; Wolkowitz et al. 1988 ), these results may merely reflect regression toward the mean. In deciding whether or not to use these medications, it should be noted that they are potentially addictive and that withdrawal may be a problem, particularly with high-potency triazolobenzodiazepines with short half-lives such as alprazolam. There is evidence that some schizophrenic patients show psychotic exacerbations in response to benzodiazepines (Dixon et al. 1989) .
There have been three reports of the effect of the anticonvulsant benzodiazepine clonazepam in schizophrenia. Karson and colleagues (1982) reported worsening of aggressive symptoms in four of nine chronic schizophrenic patients treated with clonazepam. Altamura and colleagues (1987) found clonazepam to be superior to placebo in 24 haloperidol-treated schizophrenic patients as indicated by earlier BPRS total score. However, no difference was noted after 4 weeks of treatment. A case study reported possible clonazepamrelated improvement in two chronic patients who failed to respond to a variety of antipsychotic agents (Raines and Greenspan 1987).
In conclusion, there is minimal evidence from controlled studies suggesting that benzodiazepines, when added to neuroleptics, are effective in 528 SCHIZOPHRENIA BULLETIN treatment-resistant patients. However, individual patients may benefit. The type of benzodiazepine does not seem to be particularly important. However, it may be that a trial of a benzodiazepine or triazolobenzodiazepine is indicated in some patients, especially during acute phases when anxiety is a prominent feature. Similar conclusions have been reached by Christison and colleagues (1991) , who provide an excellent review of controlled trials with benzodiazepines in schizophrenia.
Carbamazepine and Valproic Add. Carbamazepine has been used mainly in schizophrenic patients with EEG abnormalities, a history of violence, or both. Hakola and Laulumma (1982, 1984) were the first to report on a beneficial effect of carbamazepine, an anticonvulsant, in schizophrenic patients with abnormal EEGs and a pattern of violent behavior. Neppe (1983) , in a double-blind trial, reported beneficial effects of carbamazepine in 9 of 13 schizophrenic patients, most of whom were also receiving neuroleptic drugs. All the patients had EEG abnormalities. Ballenger and Post (1984) also reported favorable results in six cases of schizophrenia with abnormal EEGs. Luchins (1983) reported that carbamazepine diminished violent episodes in six of seven chronic schizophrenic patients, none of whom had abnormal EEGs. These results were replicated in a larger sample (Luchins 1984) . Carbamazepine has also been reported in a double-blind trial to be of some value in reducing excitement, tension, and unusual thought content in schizoaffective manic patients (Klein et al. 1984) . Carbamazepine was found to have a modest effect in decreasing excitement, manic-type symptoms, and suspiciousness in a placebo-controlled double-blind trial of 162 neurolepticresistant schizophrenic or schizoaffective patients. Carbamazepine was most useful in patients with aggressive behavior or paranoid symptomatology (Okuma et al. 1989) .
There is some evidence that carbamazepine may have a pharmacokinetic interaction with haloperidol leading to a significant decrease in plasma haloperidol levels (Jann et al. 1985; Kidron et al. 1985) . Dose and colleagues (1987) reported positive results of carbamazepine in a doubleblind trial in neuroleptic-treated schizophrenia, but Kidron and colleagues (1985) did not find a difference between placebo and carbamazepine in a double-blind trial. Herrera and colleagues (1987) also found little benefit of carbamazepine in five of six treatment-resistant schizophrenic patients. Schulz and colleagues (1990) reported the results of a trial in which 61 patients diagnosed as schizophrenic or schizoaffective by DSM-III (American Psychiatric Association 1980) criteria were treated with haloperidol alone for 4 weeks. Forty-four patients completed the trial, 17 of whom were classified as neuroleptic nonresponders because of a BPRS score of 40 or higher at the end of the trial. Carbamazepine was added in six of the patients, two of whom showed a significant decrease in total BPRS scores. As has been previously discussed, eight of the haloperidol nonresponders were treated with lithium supplementation, which was not significantly different from carbamazepine. In a recent study, Carpenter and colleagues (1991) found no evidence that carbamazepine by itself was useful as a maintenance treatment of schizophrenic patients, even those with episodic dyscontrol behaviors.
In summary, carbamazepine may be tried as an adjunct to neuroleptic treatment, especially when any evidence of an EEG abnormality, episodic violence, or manic-type symptomatology is present. It should never be used with clozapine because of the risk of combined toxic effects on blood cell precursors. When carbamazepine is used, it may be useful to monitor plasma levels of the neuroleptic agents and, if necessary, increase the dose to compensate for the possible decrease induced by the anticonvulsant.
Valproic acid is another anticonvulsant drug that has proven to be useful in the treatment of mood disorders (Pope et al. 1991) and may be of value in some neuroleptic refractory schizophrenic patients. Wassel and colleagues (1989) reported that three nonresponding schizophrenic patients responded when valproate was added to their neuroleptic treatment. Other studies have produced much less positive results (Linnoila et al. 1976; Gundurewa et al. 1980; Lautin et al. 1980; Ko et al. 1985) . Valproate may be of value as an anticonvulsant if such treatment is needed during the course of clozapine treatment.
Reserpine. There have been four double-blind studies of reserpine alone in severely ill schizophrenic patients. Three of these studies reported highly favorable results (Hollister et al. 1955; Naidoo 1956; Finn et al. 1958 ) and one did not (Gore et al. 1957) . These studies were done in the early years of neuroleptic treatment so it cannot be assumed that the patients were from the resistant group of schizophrenic subjects.
Initial reports suggested that the combined use of reserpine and neuroleptics was of some value in therapyresistant schizophrenic patients (Barsa and Kline 1955, 1956; Kinross-Wright 1955) . A subsequent review of early studies of reserpine and neuroleptic drug combinations found that the combination produced more EPS without additional therapeutic benefit compared to neuroleptics alone (Freeman 1967) . Two recent open trials reported that reserpine potentiated the action of neuroleptic drugs in refractory schizophrenic patients. Bacher and Lewis (1978) and Berlant (1986) reported 48 percent (n = 25) and 50 percent (n = 36) response rates, respectively. However, Perenyi and colleagues (1988) reported that reserpine, 1 mg/day, conferred no benefit over neuroleptics alone in 12 hospitalized, neuroleptic-resistant chronic schizophrenic patients. The use of reserpine in combination with a neuroleptic may produce severe EPS. The dose of reserpine must be carefully titrated (usually 1-5 mg/day) and onset of action may be slow (Christison et al. 1991) .
Lithium. The use of lithium in schizophrenia has been reviewed by Donaldson and colleagues (1985) and Schulz and colleagues (1990) . There is evidence that some schizophrenic patients may respond to lithium, especially those who are not excited (Johnson et al. 1968; Braden et al. 1982 ), but there is no evidence that treatment-resistant patients are included among the group of lithium responders. Several studies have reported that adding lithium to the regimens of patients who were partial responders to neuroleptic drugs led to improvement in psychotic symptoms (Small et al. 1975; Biederman et al. 1979; Carman et al. 1981) . Lewis and colleagues (1986) reported that lithium produced moderate improvement in dysphoria with no effect on positive or negative symptoms in a group of 12 chronic patients who were poor responders to neuroleptic drugs. Delva and colleagues (1982) withdrew lithium from six patients with chronic schizophrenia who were also receiving neuroleptic drugs. Two of the six relapsed, then responded to reintroduction of lithium and relapsed again when lithium was withdrawn on a double-blind basis. There is some evidence that schizophrenic patients with depressive symptoms are better candidates for lithium augmentation than other subgroups (Lerner et al. 1988 ). However, this conclusion was based on newly admitted patients and may not hold for treatmentresistant schizophrenic patients.
Antidepressant Drugs. Schizophrenic patients often have depressive symptoms during the course of their illness. This may be during or following an acute exacerbation in the early stages of their psychosis. During the later stages of the illness, it may be difficult to distinguish depressive from negative symptoms or the effect of neuroleptics. Schizoaffective depressed patients have these symptoms much more intensively than patients with other types of schizophrenia using DSM-Hl-R criteria (American Psychiatric Association 1987), but they occur in schizophrenic patients as well.
There is some evidence that tricyclic antidepressants may decrease depressive symptoms in postpsychotic depression. Siris and colleagues (1987) reported that imipramine was superior to placebo in terms of CGI and specific depressive symptoms in 33 depressed schizophrenic outpatients who were not psychotic and who had not responded to antiparkinsonian medication tried first to rule out neuroleptic-induced psychomotor effects as a possible cause of the depressive syndromes. Positive results in similar patients have also been reported by Prusoff and colleagues (1979) and Singh and colleagues (1978) , but not by others (Waehrens and Gerlach 1980; Johnson 1981; Kurland and Nagaraju 1982) . There is no evidence that antidepressant drugs are useful in the acute phase or in chronically hospitalized schizophrenic patients (Becker 1983; Donaldson et al. 1985; Kramer et al. 1989 ). Bucci (1987) reported that tranylcypromine, a monoamine oxidase inhibitor, markedly improved negative symptoms in 15 chronic patients who were treated with neuroleptics and had mainly negative symptoms. A comparison group showed no change in negative symptoms until tranylcypromine was added. More recently, Goff and colleagues (1990) reported that fluoxetine, in doses of 20 mg, was of benefit in treating positive and negative symptoms in therapy-resistant schizophrenic patients. Controlled trials are needed to replicate these interesting results.
In our clinical experience, clozapine has had a very beneficial effect in many treatment-resistant patients with depressive symptoms. If depressive symptoms are a major feature of the disorder in an otherwise neuroleptic-responding patient, it might be useful to give a 6-week trial of a tricyclic antidepressant. If positive and negative symptoms have also responded poorly to trials of two or more classes of typical neuroleptic drugs, a trial of clozapine would be of use.
L-Dopa and (/-Amphetamine. These studies have been reviewed by us elsewhere ) and by Christison and colleagues (1991) . L-dopa and d-amphetamine act mainly to increase dopaminergic activity and may be of benefit, especially in patients with marked negative symptoms and few positive symptoms (Inanaga et al. 1972; Gerlach and Luhdorf 1975; Brambilla et al. 1979; Cesarec and Nyman 1985) . Exacerbations of positive symptoms may occur in some patients (Yaryura-Tobias et al. 1970; Angrist et al. 1973; Calil et al. 1977) . Concomitant neuroleptic treatment did not preclude the beneficial effect of L-dopa or d-amphetamine. It has been suggested that neuroleptic withdrawal may be cautiously tried in those patients who respond to L-dopa. Further study of these agents with typical neuroleptic drugs and clozapine would be of interest using more sophisticated rating scales and better research designs, including explicit definitions of treatment resistance. There have been studies of bromocriptine (a direct acting DA agonist) plus neuroleptics in schizophrenia (e.g., Meltzer et al. 1983b ), but not in treatment-resistant schizophrenia.
Opioid Drugs. Morphine was commonly used to treat schizophrenia at the turn of the century but gradually was abandoned. Beneficial effects of opioid antagonists such as maltrexone (Ragheb et al. 1980) or naloxone Pickar 1983) have been reported, but controlled studies show no overall efficacy (Pickar et al. 1989) . Methadone has also been reported to be of some value in neuroleptic-resistant paranoid schizophrenic patients (Brizer et al. 1985) . Neither approach can be recommended in treatment-resistant schizophrenic patients except as a last resort when clozapine and other better-studied approaches have been exhausted. Calcium Channel Blockers. There has been some interest in the possibility that neuroleptic drugs that are calcium channel blockers may be more effective in treating the negative symptoms of schizophrenia than those that are weak in this regard (Gould et al. 1983) . On this basis, verapamil, a calcium channel blocker of the papaverine subtype, was tested against placebo in a doubleblind trial in 15 poorly responsive neuroleptic-treated schizophrenic patients. There was no effect on positive or negative symptoms (Grebb et al. 1986 ). Negative results with verapamil were also reported by Schepelern and Koster (1987) . Verapamil was also ineffective by itself in seven chronic schizophrenic patients (Pickar et al. 1987 ). There are two uncontrolled studies that found slightly beneficial effects from the addition of verapamil (Tourjman et al. 1987; Reiter et al. 1989) and one that showed positive effects with nifedipine (Stedman et al. 1991) . In the latter study, improvement in TD was also reported.
Other Pharmacologic Approaches to the Treatment-Resistant Schizophrenic Patient. A variety of agents have been tried with and without neuroleptic agents in treatmentresistant schizophrenic patients, including ultra high doses of the betaadrenergic blocker propranolol (Bigelow et al. 1978; Lindstrom and Persson 1980; Pugh et al. 1983) . The evidence suggests no consistent benefit from this regimen. The alpha 2 -agonist clonidine (Freedman et al. , 1982 , the alphaj antagonist prazosin (Hommer et al. 1984b) , GABAergic drugs such as di-npropyl-acetate (Linnoila et al. 1976 ), baclofen (Simpson et al. 1976 ), gamma-acetylenic acid (Casey et al. 1980 ), gamma-vinyl-GABA (Korsgaard et al. 1983 Stahl et al. 1985) , thyrotropin-releasing hormone (Wilson et al. 1973 ), lysine-8-vasopressin (Korsgaard et al. 1981 ), cholecystokinin (Itoh et al. 1982 Bloom et al. 1983; Hommer et al. 1984a; Mattes et al. 1985a , 1985b ), beta-endorphin (Gerner et al. 1980 Pickar et al. 1981) have also been tried. These studies have been reviewed by us elsewhere ). There is little reason to believe that any of these therapies provides any advantages over clozapine. Claims of their efficacy in specific studies have generally been modest and often not replicable. However, individual patients may benefit from some of these therapies because the pathophysiology of schizophrenia in their cases varies from the majority. As there are no predictors of who these patients are, only adequate clinical trials could identify them. If clinicians do attempt such trials, they would be advised to withdraw the agent if apparent efficacy develops to establish that the agent is, in fact, beneficial.
Among the agents listed, the most likely candidates for such trials appear to be high-dose propranolol and clonidine. At the doses used, propranolol has many actions other than beta-adrenergic blockade, including 5-HT 1A antagonism.
Electroconvulsive Therapy (ECT). ECT was at one time frequently used in the treatment of schizophrenia. There is some evidence that ECT is of value in treating acute schizophrenic patients, especially those with catatonic or affective symptoms. According to Salzman (1980) , there is minimal evidence supporting the use of ECT in treatment-resistant schizophrenia, either alone or as an adjunct to VOL. 18, NO. 3, 1992 531 treatment in patients receiving typical neuroleptic drugs. ECT may sometimes produce improvement in symptomatology in these patients, but the response is usually transient and is followed by relapse. The estimated rate of response is 5 to 10 percent, which is obviously low but not so low as to preclude a trial if clozapine is unsuccessful or not available. Multiple maintenance treatments are necessary to achieve sustained improvement, and this raises the hazard of serious memory loss. Unilateral, nondominant hemisphere ECT should be used if such a course of treatment is attempted. Gujavarty and colleagues (1987) reported that seven of eight patients with schizophrenia who had failed to respond to two previous courses of neuroleptics responded when ECT was added to neuroleptic treatment. It was suggested that this was due to the ability of the ECT to increase the permeability of the blood-brain barrier to neuroleptic drugs, thereby increasing the concentration of brain levels of neuroleptic drugs. It should be noted that five of these eight patients had a history of affective symptomatology. The duration of illness ranged from 2 to 25 years (median = 3.25 years). The median age of the patients was 23. Thus, this was a relatively young group and would not be representative of the larger group of treatmentresistant schizophrenic patients. The presence of affective symptoms raises the question that this group was more schizoaffective than schizophrenic. It is questionable that an increase in the blood-brain barrier permeability is responsible for whatever benefits ECT may produce in neuroleptic-treated schizophrenic patients.
Friedel (1986) treated nine neuroleptic nonresponding schizophrenic patients with unilateral or bilateral ECT three times per week. Eight patients reportedly achieved a complete remission of psychotic symptoms and were able to be discharged. Between 8 and 25 treatments were administered (mean = 13.6). The results were equivalent with both unilateral and bilateral ECT: the duration of remission with unilateral ECT was 4.6 months compared to 6.5 months with bilateral ECT. Milstein and colleagues (1990) reported retrospectively the results of an open study of ECT in 110 patients with diagnoses of schizophrenia (n = 85) or schizoaffective disorder (n = 28) who had failed to respond to other therapies or who had intolerable side effects. Most of the patients (88%) were receiving concomitant antipsychotic medication. Sixty (54.6%) of the patients were considered to be responders by clinical criteria. There were no data presented on the duration of the response to ECT. We have recently administered a course of ECT to six treatment-resistant schizophrenic patients, five of whom (83.3%) had a moderate-to-good response with significant improvement in positive and negative symptoms (Meltzer and Sajatovic, submitted for publication). With monthly maintenance ECT, two of four patients had a sustained improvement and two relapsed.
In summary, there is modest evidence to support the use of ECT in treatment-resistant schizophrenia. A history of affective symptoms may indicate a better prognosis. It should, in the author's opinion, be considered only as a last resort, after all pharmacologic approaches have been systematically considered.
Psychosurgery. Since the 1920s, psychosurgical procedures of various types have been used in schizophrenic patients who failed to respond to whatever other therapies were available in each era. The most commonly used procedure has been the prefrontal lobotomy and other discrete ablations of frontal lobe and other mesocortical areas. As reviewed by Sweet (1973) and May (1974) , there was some evidence for a nonspecific effect in schizophrenia, especially for affective symptoms, but the results were not impressive and such operations have virtually disappeared. Cingulotomy is also thought to have value for affective symptoms in some schizophrenic patients (Ballantine et al. 1987) .
Psychosurgery for schizophrenia is considered strictly a research procedure today. However, it is not inconceivable that focal operations of an ablative nature, to insert drugs directly into the brain or to implant cell lines capable of producing neurotransmitters, might be tried for clozapine-refractory schizophrenia, particularly if research on brain function in the biology of schizophrenia leads to a novel hypothesis.
Sequence of Therapies for the Treatment-Resistant Patient
The initial approach to the schizophrenic patient who is treatment resistant should be to confirm the diagnosis by careful psychiatric examination and medical workup. A thorough psychiatric history and clinical interview guided by a structured schedule such as the Schedule for Affective Disorders and Schizophrenia (SADS; Endicott and Spitzer 1978) may be helpful. Occasionally, misdiagnosed affective disorders, chronic anxiety disorders, obsessivecompulsive disorder, and organic disorders such as frontal lobe tumors or temporal lobe epilepsy will be found. Response to neuroleptic or 532 SCHIZOPHRENIA BULLETIN other therapies should not be used as part of diagnostic assessment.
After the diagnosis of schizophrenia is made, the next step is to assess the response to neuroleptic treatment. First, the dose and duration of treatment must be assessed. Compliance may be ensured by route of administration or determination of drug, plasma, or prolactin levels. Measurement of drug levels in plasma will be needed to assess bioavailability. A trial of a given agent should last at least 6 weeks. Dosage is more difficult to recommend because of the paucity of data about the dose-response range for many drugs, the possible adverse effect of too high doses, adjustment of dose for body weight and ethnicity, and the effect of concomitant medications. The optimal dose range of haloperidol appears to be 10 to 20 mg/day, but this may be too low or too high for many patients. Haloperidol equivalencies in man have often been reported (Davis 1974) but are probably much less accurate than is generally believed because of their derivation from clinical trials that did not adequately assess dose-effect relationships. For patients intolerant to neuroleptic drugs because of EPS, thioridazine may be beneficial. Lowpotency neuroleptic drugs such as thioridazine may, however, be used in inadequate dosages, while the reverse is true of high-potency drugs, which may be used in excessive dosages that diminish the extent of clinical response (Baldessarini et al. 1984 (Baldessarini et al. , 1988 Response should be evaluated by a broad set of criteria: (1) positive, negative, depressive, and anxiety symptoms; (2) social function; (3) capacity for work and school; (4) ability to live in the least restrictive environment; and (5) neuropsychological function-memory, attention, etc. There is no absolute rule as to what should be considered poor response. This will be a decision made by the patient, the family, input from other clinical staff of inpatient settings, and formal neuropsychological testing. Severe hallucinations, pervasive delusions, anhedonia, depression, withdrawal, avolition, impairment of attention, and other symptoms are unequivocal criteria for treatment resistance.
A trial of clozapine is clearly indicated after neuroleptic resistance or intolerance has been established. As we have described, this trial should last up to 6 months even if improvement in symptoms is not initially observed. Clozapine potentiation may be tried with agents such as haloperidol, lithium, and buspirone, but there are no data to indicate whether any of these will be effective.
Because some public agencies are reluctant to pay for the weekly WBC counts that are needed with clozapine use, clozapine may not be available to many treatment-resistant patients. For these individuals, it may be desirable to begin sequential trials of the adjunctive treatments reviewed here. The choice of which one to start first will depend in large part on the clinical picture. Treatments and indications are outlined in table 4. These treatments may be effective in only a small proportion of patients. It is imperative that they be tried one at a time for at least 4 to 6 weeks. If they appear to be beneficial, it might still be worthwhile to withdraw them to see if the apparent benefits are drug related. Relapse is good evidence for efficacy and treatment should be reinstituted.
If a patient has major symptomatology despite the sequential addition of each of the drugs or other treatments in table 4 to standard neuroleptic treatment, the practitioner should consider simultaneous use of several of these treatments along with neuroleptics. This should be done with the utmost caution. Choice of the second agent should include close attention to drug interactions and known mechanisms of action. For example, lithium and antidepressants have been given together safely and may have synergistic effects. On the other hand, the combination of carbamazepine and valproate would not be desirable. Close monitoring for side effects based on pharmacodynamic and pharmacokinetic interactions will be critical in these trials. It is intuitively unreasonable to give a patient more than three psychotropic drugs simultaneously. The effect of such combinations on neural transmission will usually be unknown. Further, it will be virtually impossible to determine whether all of the agents are, in fact, necessary for any benefits that may emerge. Finally, there is a greater possibility of severe side effects.
Neuroleptic Intolerance: EPS and TD
Neuroleptic drugs vary in their capacity to produce EPS at clinically equivalent doses (Baldessarini et al. 1984) . Individual patients also vary in their propensity to develop EPS (Keepers and , probably due to endogenous reserve of dopaminergic activity (Crowley et al. 1978) and other mechanisms that can overcome the effect of D 2 receptor blockade. There is evidence that the degree of striatal D 2 receptor blockade produced by antipsychotic drugs is a crucial determinant of EPS (Farde et al., in press ). If patients develop acute or subacute EPS, there are three strategies to alleviate the problem: lower the dosage, switch drugs, or add an antiparkinsonian agent. Lowering the dosage should be tried first. If psychosis breaks through or cannot be controlled, switching to thioridazine, which has the fewest EPS of any currently marketed antipsychotic drug, may be of value. However, its sedative and hypotensive properties may be intolerable to some patients. The use of anticholinergic drugs or amantadine to reduce EPS is well established. These drugs, however, may be stimulating to some patients. Recently, the 5-HT 2 antagonist ritanserin has been suggested for EPS (Bersani et al. 1990 ), but it is not available in many countries. When all these measures fail to make it possible for relapse-prone patients to accept doses of antipsychotic drugs, a clozapine trial would appear to be justified.
Conclusions
Treatment resistance of schizophrenic patients to typical neuroleptic drugs can be due to a variety of factors other than an intrinsic lack of response to the neurobiological effects of standard drug treatment. Lack of response may be due to pharmacokinetic factors as well as persistent, severe psychosocial stressors. Assuming such factors have been addressed and excluded, a trial of clozapine alone for up to 6 months is indicated. If this is not possible or proves unsuccessful, a variety of other agents may be considered as supplements to standard neuroleptic treatment. The choice depends on symptomatology. ECT may be the most helpful if positive symptoms are persistent. These ancillary therapies should not be continued unless there is clear evidence that they are beneficial. This may require, in some instances, stopping them to see if the apparent benefits require their presence. International Clinical Psychopharmacology, 5:287-290, 1990 . Altamura, A.C.; Mauri, M.C.; Mantero, M.; and Brunetti, M. Clonazepam/haloperidol combination therapy in schizophrenia: A double-blind study. Ada Psychiatrica Scandinavica, 76:702-706, 1987 
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